Cargando…
Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
Pulmonary hypertension is one of the difficult situations to treat. Complex pathophysiology, association of the multiple comorbidities make clinical scenario challenging. Recently it is being shown that patients who had recovered from coronavirus disease infection, are at risk of developing pulmonar...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171713/ https://www.ncbi.nlm.nih.gov/pubmed/35500734 http://dx.doi.org/10.1016/j.cpcardiol.2022.101236 |
_version_ | 1784721726947459072 |
---|---|
author | Hajra, Adrija Safiriyu, Israel Balasubramanian, Prasanth Gupta, Rahul Chowdhury, Selia Prasad, Abhishek J. Kumar, Akshay Kumar, Deepak Khan, Baseer Bilberry, Roberta S.F. Sarkar, Ankit Malik, Paras Aronow, Wilbert S. |
author_facet | Hajra, Adrija Safiriyu, Israel Balasubramanian, Prasanth Gupta, Rahul Chowdhury, Selia Prasad, Abhishek J. Kumar, Akshay Kumar, Deepak Khan, Baseer Bilberry, Roberta S.F. Sarkar, Ankit Malik, Paras Aronow, Wilbert S. |
author_sort | Hajra, Adrija |
collection | PubMed |
description | Pulmonary hypertension is one of the difficult situations to treat. Complex pathophysiology, association of the multiple comorbidities make clinical scenario challenging. Recently it is being shown that patients who had recovered from coronavirus disease infection, are at risk of developing pulmonary hypertension. Studies on animals have been going on to find out newer treatment options. There are recent advancements in the treatment of pulmonary hypertension. Role of anticoagulation, recombinant fusion proteins, stem cell therapy are emerging as therapeutic options for affected patients. SGLT2 inhibitors have potential to have beneficial effects on pulmonary hypertension. Apart from the medical managements, advanced interventions are also getting popular. In this review article, the authors have discussed pathophysiology, recent advancement of treatments including coronavirus disease patients, and future aspect of managing pulmonary hypertension. We have highlighted treatment options for patients with sleep apnea, interstitial lung disease to discuss the challenges and possible options to manage those patients. |
format | Online Article Text |
id | pubmed-9171713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91717132022-06-07 Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension Hajra, Adrija Safiriyu, Israel Balasubramanian, Prasanth Gupta, Rahul Chowdhury, Selia Prasad, Abhishek J. Kumar, Akshay Kumar, Deepak Khan, Baseer Bilberry, Roberta S.F. Sarkar, Ankit Malik, Paras Aronow, Wilbert S. Curr Probl Cardiol Article Pulmonary hypertension is one of the difficult situations to treat. Complex pathophysiology, association of the multiple comorbidities make clinical scenario challenging. Recently it is being shown that patients who had recovered from coronavirus disease infection, are at risk of developing pulmonary hypertension. Studies on animals have been going on to find out newer treatment options. There are recent advancements in the treatment of pulmonary hypertension. Role of anticoagulation, recombinant fusion proteins, stem cell therapy are emerging as therapeutic options for affected patients. SGLT2 inhibitors have potential to have beneficial effects on pulmonary hypertension. Apart from the medical managements, advanced interventions are also getting popular. In this review article, the authors have discussed pathophysiology, recent advancement of treatments including coronavirus disease patients, and future aspect of managing pulmonary hypertension. We have highlighted treatment options for patients with sleep apnea, interstitial lung disease to discuss the challenges and possible options to manage those patients. Elsevier 2023-08 2022-04-29 /pmc/articles/PMC9171713/ /pubmed/35500734 http://dx.doi.org/10.1016/j.cpcardiol.2022.101236 Text en . Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hajra, Adrija Safiriyu, Israel Balasubramanian, Prasanth Gupta, Rahul Chowdhury, Selia Prasad, Abhishek J. Kumar, Akshay Kumar, Deepak Khan, Baseer Bilberry, Roberta S.F. Sarkar, Ankit Malik, Paras Aronow, Wilbert S. Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension |
title | Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension |
title_full | Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension |
title_fullStr | Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension |
title_full_unstemmed | Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension |
title_short | Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension |
title_sort | recent advances and future prospects of treatment of pulmonary hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171713/ https://www.ncbi.nlm.nih.gov/pubmed/35500734 http://dx.doi.org/10.1016/j.cpcardiol.2022.101236 |
work_keys_str_mv | AT hajraadrija recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT safiriyuisrael recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT balasubramanianprasanth recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT guptarahul recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT chowdhuryselia recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT prasadabhishekj recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT kumarakshay recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT kumardeepak recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT khanbaseer recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT bilberryrobertasf recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT sarkarankit recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT malikparas recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension AT aronowwilberts recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension |